Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
4/2019 ceased to operate
Bioblast Pharma
Bioblast Pharma Overview
Bioblast Pharma is a biotechnology company that develops therapies for patients with rare and ultra-rare genetic diseases. The company is building a diverse portfolio of product candidates with the potential to treat patients with incurable rare diseases.
Cabaletta is a mutant protein-stabilizing platform based on a small repurposed molecule. Mutant unstable cellular proteins are the cause of several genetic diseases known as PolyA/Poly Q, including OPMD, SBMA, and SCA3.
BBrm is a read-through platform based on a small repurposed molecule. The platform enables the read-through (or bypassing) of genetic defects, called nonsense mutations or stop codons, that interfere with normal protein formation.
mPRT is a mitochondrial protein replacement platform based on biological fusion proteins. The platform is aimed at mitochondrial protein deficiency diseases and is capable of replacing missing or mutated proteins in mitochondria and restoring cell function.
In March 2019, Enlivex Therapeutic which is developing a treatment for graft versus host disease, a deadly side effect of bone marrow transplants, has announced the completion of its merger into Nasdaq stock exchange shell Bioblast Pharma.
Bioblast Pharma Climate Tech relevance
undefined
Companies you might be interested in
Driven by Finder AI
Latest News
No Data, yet.
Sorry, no content found under this section.
Mar 28, 2019
en.globes.co.il
Enlivex raises $5.3m on Nasdaq, merges with Bioblast
#Acquisition #Investment
Jul 30, 2015
www.israel21c.org
Drug for rare muscular dystrophy fast-tracked
#Customers
Jul 15, 2014
www.nasdaq.com
Rare disease biotech Bio Blast Pharma sets terms for $40 million IPO